Voyager Therapeutics, Inc.
VYGR
$3.25
-$0.15-4.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 22.06% | -83.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.06% | -83.09% | |||
| Cost of Revenue | -10.41% | -26.68% | |||
| Gross Profit | 14.24% | -20.82% | |||
| SG&A Expenses | -9.02% | 0.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.06% | -21.32% | |||
| Operating Income | 12.81% | -14.52% | |||
| Income Before Tax | 12.43% | -1.85% | |||
| Income Tax Expenses | 42.86% | 55.56% | |||
| Earnings from Continuing Operations | 12.40% | -1.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.40% | -1.86% | |||
| EBIT | 12.81% | -14.52% | |||
| EBITDA | 13.14% | -15.58% | |||
| EPS Basic | 13.93% | -0.92% | |||
| Normalized Basic EPS | 13.94% | -15.65% | |||
| EPS Diluted | 13.93% | 0.13% | |||
| Normalized Diluted EPS | 13.94% | -15.65% | |||
| Average Basic Shares Outstanding | 1.77% | 0.95% | |||
| Average Diluted Shares Outstanding | 1.77% | 0.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||